Phase II trial

Parkinson's disease
#BioVie #Neuroscience #Parkinson's #Phase II trial

Trial shows significant improvements in early Parkinson’s disease

BioVie has announced results from its Phase II SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease (PD).  The SUNRISE-PD trial was a Phase II, multicentre, randomised, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in patients with early-stage PD that had not previously… Read More

#Editor's Choice #News

#Elicio Therapeutics #KRAS #Oncology #Pancreatic cancer #Phase II trial

Elicio refines its Phase III strategy for ELI-002 7P in pancreatic cancer

Elicio Therapeutics has reported that its Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet its endpoint of disease-free survival (DFS).   However, the company says landmark analyses during active ELI-002 7P treatment indicated early treatment benefit. Post-hoc… Read More

#Cancer Research #News

Human liver
#Liver disease #OrsoBio #Phase II trial

LXR inverse agonist shows promise in liver disease

A liver-targeted LXR inverse agonist has been found to produce rapid, substantial reductions in triglycerides in patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction-associated steatoticliver disease (MASLD).  OrsoBio presented the results from its Phase IIa proof-of-concept study of TLC-2716 at the Endocrine Society’s Annual Meeting (ENDO 2026). Read More

#News

Neuroscience Parkinson's disease
#Autobahn Therapeutics #Bipolar #Neuroscience #Phase II trial #Psychiatry

Bipolar treatment leads to rapid antidepressant effects

A treatment for patients with bipolar I or bipolar II depression has demonstrated durable antidepressant effects, results show. Elunetirom, developed by Autobahn Therapeutics, is a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist. In the Phase II AMPLIFY-BD trial, elunetirom was evaluated as an adjunctive… Read More

#News

Cancer cells
#Oncology #Phase II trial #Repertoire Immune Medicines #Solid tumours

Repertoire initiates trial of T cell-targeted immune medicine

Repertoire Immune Medicines has dosed the first participant in a Phase I/II clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid tumours.   The trial is being conducted at multiple clinical sites in the United States and Europe following clearance of Repertoire’s Investigational… Read More

#Cancer Research #Editor's Choice #News

Blood cells
#Monoclonal antibodies #Phase II trial #Rare disease #Takeda

NEJM data support Takeda’s treatment for ITP

The New England Journal of Medicine (NEJM) has published final results from a Phase II study evaluating Takeda’s mezagitamab (TAK-079), an investigational treatment option for patients with primary immune thrombocytopenia (ITP).  The NEJM-published data showed patients treated with mezagitamab achieved:  … Read More

#News

Institute of Cancer Research
#Oncology #Oncolytic virus #Ovarian cancer #Phase II trial

Oncolytic immunotherapy could offer new option in ovarian cancer

Biotechnology firm Theolytics has been awarded €8 million research funding through the Horizon Europe programme, to support expansion of the OCTOPOD‑IV Phase IIa trial in platinum‑resistant ovarian cancer.  The trial will evaluate THEO‑260 — a next‑generation oncolytic immunotherapy designed… Read More

#Cancer Research #News

Hydrogel
#Phase II trial #SolasCure

Gel could heal chronic wounds seven times faster, data shows 

A new gel could heal chronic wounds seven times faster than current standard of care, data suggests.  Biotechnology company SolasCure has released data from its Phase II trial of the Aurase Wound Gel (AWG), showing the gel demonstrated 22 times faster debridement and seven times faster healing compared to standard of care.  … Read More

#News

Blood cancer
#Myeloma #Oncology #Phase II trial #Starton Therapeutics

STAR-LLD seeks to replace standard care for blood cancers

Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM).  STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple… Read More

#Cancer Research #News

Crohn's disease
#Amorphical #Crohn's disease #Inflammatory Bowel Disease #Phase II trial

Novel non-immunosuppressive approach for Crohn’s

Amorphical has announced positive final long-term follow-up data from its Phase II clinical trial evaluating its investigational nano-amorphous Calcium Carbonate (ACC) therapy, for the treatment of moderate-to-severe Crohn’s disease.  The full data analysis, including a cohort of patients who completed follow-up extending up to 48 weeks post-baseline,… Read More

#News

#Cancer treatment #Intensity Therapeutics #Oncology #Phase II trial #Solid tumours

Intratumoral injection drives local and systemic anti-cancer activity

eBioMedicine, a Lancet Discovery Science journal, has published Intensity Therapeutics’ Phase I/II IT-01 clinical study manuscript for the treatment of metastatic or refractory cancers.   According to the data, in heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following… Read More

#Cancer Research #News

Dementia
#Dementia #Neurodegenerative disorders #Phase II trial #Vesper Bio

First oral therapy for frontotemporal degeneration shows promise

Positive topline results from Vesper Bio’s Phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic carriers with frontotemporal degeneration (FTD) caused by mutations in the progranulin gene (GRN).  Mean progranulin levels increased by more than 95% compared to baseline at the highest dose tested.   As… Read More

#Editor's Choice #News

Lung cancer
#BioNTech #Bristol Myers Squibb #Lung cancer #Oncology #Phase II trial

Bispecific antibody trial shows encouraging antitumour activity

BioNTech and Bristol Myers Squibb have revealed global interim Phase II data for their PD-L1xVEGF-A bispecific antibody pumitamig in patients with extensive-stage small cell lung cancer (ES-SCLC) which shows encouraging antitumour activity.  The data for pumitamig plus chemotherapy showed a 76.3% confirmed objective response rate (cORR), 100%… Read More

#Cancer Research #News

Fibrosis lungs
#3D imaging #Artificial intelligence (AI) #Calluna Pharma #Idiopathic pulmonary fibrosis #Imaging #Phase II trial #Qureight

AI 3D imaging platform supports Calluna’s IPF trial

Calluna Pharma will use Qureight’s AI-powered imaging and clinical data curation platform to support its Phase II AURORA study.   Qureight will analyse imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF). Read More

#News

#FDA #Gene therapy #Phase II trial #Rare disease #Rocket Pharmaceuticals

FDA lifts hold on Rocket Pharma’s Phase II trial of RP-A501

The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease.  The hold was lifted in under three months and led to an increase in  Rocket’s stock value by 30%. … Read More

#News